Rational selection of antigenic targets for Group A Streptococcus vaccine: updates, challenges and opportunities.
Researchers
Melaku Ashagrie Belete, Istvan Toth, Rachel Stephenson, Mariusz Skwarczynski
Abstract
Group A Streptococcus (GAS) remains a major global health challenge, causing over half a million deaths annually. Despite nearly a century of research, no licensed vaccine is currently available, due to antigenic diversity, complex host-pathogen interactions, risk of autoimmunity and lack of clear correlates of protection. This review discusses recent advances in GAS vaccine research, highlights key challenges and outlines criteria and emerging opportunities for antigen selection.Source: PubMed (PMID: 41997948)View Original on PubMed